Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus TP in locally advanced resectable oral squamous cell carcinoma (Phase II, single-arm)
ChiCTR2200064609Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Oct 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in Oral Mucosal Carcinoma, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Complete pathological response rate. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2200064609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064609.